Scientific Program
ATTD is the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes, assemble with the aim to be share knowledge and develop collaborations.
Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.
Click to review the scientific program schedule
Interactive ProgramProgram at a Glance*Program Timetable
List of Confirmed Speakers and Topics
| Peter | Adolfsson | Sweden | Time in tight range in type 1 diabetes |
| Ramzi | Ajjan | UK | Is it easy to use time in range (TIR) for daily management of diabetes? |
| Shridhara | Alva | USA | Pre-clinical and clinical development of CGM-CKM |
| Lia | Bally | Switzerland | Physical activity with long and ultra-long-acting basal insulins |
| Katharine | Barnard-Kelly | UK | · Understanding clinical relevance on a PRO |
| · Psycho-behavioral barriers to optimal glucose management in women with T1D across the ages | |||
| Tadej | Battelino | Slovenia | Time in tight range in type 2 diabetes |
| Richard | Bergenstal | USA | Use of CGM with people with diabetes type 2 not treated with insulin |
| Rachel | Besser | UK | Screening of general population – current status around the world |
| Mithun | Bhartia | India | SWOT (Strength, Weakness, Opportunity and Threats) Analysis of Blood Sugar Monitoring in India |
| Bruce | Bode | USA | Management of Hyperglycemia in the hospital using closed-loop systems |
| Andrew | Boulton | UK | New evidence-base therapies for complex diabetic foot wounds |
| Nataša | Bratina | Slovenia | Avoiding hyperglycemia from diabetes onset |
| Marc | Breton | USA | Machine learning and big data to identify individuals at risk |
| Rodica | Busui | USA | SGLT inhibitors in T1D: DKA risk and DKA risk mitigation strategies, especially CGM-CKM, to enable therapy use for heart and kidney health |
| Eda | Cengiz | USA | Technological gadgets: What is available to girls and women with diabetes |
| Antonio | Ceriello | Italy | Cardiovascular outcome trials (CVOT): which role for risk factors control? |
| Manoj | Chawla | India | Diabetes Management in India – Challenges & Tech Solutions |
| Pratik | Choudhary | UK | Difference between CGM detected and patient reported hypoglycemia |
| Ali | Cinar | USA | Automated detection of meals and exercise events in people with diabetes |
| Mark | Clements | USA | · Population health management in the digital diabetes era |
| · Deep learning to predict diabetes outcome | |||
| Patricio | Colmegna | USA | Automated control meets behavior: human-machine co-adaptation of the artificial pancreas |
| Amy | Criego | USA | Improved data collection: moving CGM reports from the patient directly to the EMR |
| Tali | Cukierman-Yaffe | Israel | Adverse outcomes of hyperglycemia & hypoglycemia in older people with diabetes- how should the recommended target % TIR be determined? |
| Thomas | Danne | Germany | What is the clinical relevance of TIR/TAR 70-140 mg/dl for T1D and T2D? |
| Christophe | de Block | Belgium | Continuous Ketone Monitoring |
| Bastiaan | de Galan | The Netherlands | Learnings from the HypoRESOLVE |
| Lois | Donovan | Canada | Psychosocial impact of using closed-loop systems during pregnancy |
| Klemen | Dovc | Slovenia | Ultra-rapid insulin and anticipatory algorithms |
| Steven | Edelman | USA | Once weekly insulins in Type 1 diabetes: safety, efficacy and does it address an unmet need? |
| Mark | Evans | UK | The regulations around driving and diabetes |
| Chiara | Fabris | USA | Insulin dosing in women with T1D: Is there a need for tailored solutions? |
| Gregory | Forlenza | USA | Data ownership and use of data aggregators in clinical care |
| Juan P | Frias | USA | Unimolecular multiagonists (dual and triple) for the management of obesity and cardiorenal risk – An update |
| Simon | Friedman | USA | Replacing pumps with light controlled insulin delivery |
| Satish | Garg | USA | The vision of the future us of CGM in type 2 diabetes |
| Michal | Gillon-Keren | Israel | Mobile application for carbohydrate counting – personalized nutrition |
| Amit | Gupta | India | Personalized Medicine to Precision Medicine: India Is Changing |
| Ahmad | Haidar | USA | Closed-loop with adjunct therapies |
| Lutz | Heinemann | Germany | Diabetes Technology and waste: How to turn greener – for the EU |
| Simon | Heller | UK | What reduction in hypoglycemia from interventions should be considered clinically meaningful |
| Irl | Hirsch | USA | · Skin and the Insulin Pump: New Findings |
| · Update on glycemic targets in the ICU | |||
| Korey | Hood | USA | Patient reported outcomes in closed loop studies |
| Roman | Hovorka | UK | Closing the loop – from cradle to mature age |
| Peter | Jacobs | USA | · Decision support, incorporating explainability and interpretability |
| · Closed-loop next generation algorithms, leveraging AI and the smart-home | |||
| Laura | Jacobsen | USA | Emerging biomarkers of responses to immunotherapies |
| Mojca | Jensterle Sever | Slovenia | GLP-1 Analogs for the treatment of Obesity |
| Partha | Kar | UK | Strategies to tackle the deprivation gap in tech access |
| David | Kerr | USA | The greening of diabetes care in America |
| Jothydev | Kesavadev | India | Do It Yourself Artificial Pancreas: the affordable Indian experiences |
| Boris | Kovatchev | USA | Fully-automated closed-loop control: challenges and potential solutions |
| Lori | Laffel | USA | · Understanding and Overcoming Health Disparities in Use of Diabetes Technologies |
| · Addressing opportunities to Improve glycemic control and limit diabetes distress | |||
| Maya | Laron-Hirsh | Israel | Complex meal handling with advanced hybrid closed-Loop system |
| Julia | Lawton | UK | Psychological impact of technology: what is most relevant? |
| Lalantha | Leelarathna | UK | Use of CGM with people with diabetes type 2 treated with basal insulin only |
| Alon | Liberman | Israel | Fear of hyperglycemia in parents of children with type 1 diabetes |
| David | Maahs | USA | · ECHO study – Delivering tele-education on diabetes to primary care physicians in rural areas |
| · Bridging Disparities in Type 1 Care in the US | |||
| Julia | Mader | Austria | Monitoring of diabetic foot disease |
| Chantal | Mathieu | Belgium | The new face of diabetes |
| Laurel | Messer | USA | Skin integrity, tips, tricks and hacks for sustained device use |
| Viswanathan | Mohan | India | Advocacy and adoption of technology and disparities in India |
| Medha | Munshi | USA | Why healthy aging with diabetes is a challenge? Demographics and special considerations in older age |
| Helen | Murphy | UK | · Automated insulin delivery in type 1 diabetes pregnancy – are we nearly there yet? |
| · AID experience in pregnancy in the real world | |||
| Revital | Nimri | Israel | Real-World Data on the use of Decision Support systems |
| Kirsten | Nørgaard | Denmark | Exercise with AID |
| David | O’Neal | Australia | The use of Hybrid closed systems in older people with diabetes |
| Rakesh | Parikh | India | Diabetes Technology – The Make in India Story |
| John | Pemberton | UK | The issues with using CE Mark as a valid proxy for continuous glucose monitoring systems accuracy for people with type 1 diabetes |
| Sumita | Pennathur | USA | Long term solutions for improving infusion site challenges for insulin pumps |
| Sarit | Polsky | USA | Do we need pregnancy specific closed-loop algorithms? |
| Walter | Pories | USA | Bariatric surgery: an update |
| Frans | Pouwer | Denmark | The impact of hypoglycemia: what do studies using patient reported outcomes tell us |
| Richard | Pratley | USA | The use of CGM in older people with diabetes |
| Melissa | Putman | USA | Use of CGM in the Cystic Fibrosis population |
| Régis | Radermecker | Belgium | AID experience in the real world in Belgium |
| Robert | Ratner | USA | Outcomes of continuous remote care in pre-diabetes and type 2 diabetes |
| Eric | Renard | France | AID experience in the real world in French Children |
| Michael | Riddell | Canada | Closing the loop on exercise |
| David | Rodbard | USA | TIR and other Times in Ranges are better than HbA1c as metrics for quality of glycemic control |
| Julio | Rosenstock | USA | · Challenging Treatment Guidelines: Reversing Type 2 DM from Day One |
| · The use of weekly basal insulin analogue BIC in T2D | |||
| Andrea | Scaramuzza | Italy | Strategies for mitigating glycemic excursions following unannounced meals with existing technologies |
| David | Scheinker | USA | Algorithm-enabled RPM for T1D; lessons from the 4T study for a continuously learning health system |
| Oliver | Schnell | Germany | Cardiovascular outcome trials (CVOTs) in diabetes – A success story that has changed the landscape of diabetes therapy |
| Matthias Axel | Schweitzer | Germany | Diabetes Technology and waste: How to turn greener – The industry perspective |
| Jay | Skyler | USA | Stem Cell Approaches to Type 1 Diabetes |
| Darja | Šmigoc Schweiger | Slovenia | Gender differences in cardiovascular risk markers in young population with type 1 diabetes |
| Idan | Tamir | Israel | · Continuous Lactate Monitoring (CLM) – a new paradigm for monitoring high-risk diabetic patients |
| · pre-clinical development of CGM-CKM | |||
| Bruno | Thuillier | Germany | Non-invasive Glucose Monitoring: Breath, a realistic option? |
| Marissa | Town | USA | What matters to the person with diabetes when choosing diabetes technologies |
| Prash | Vas | UK | Developing a functional multidisciplinary foot service of the future: Integrating team working and technology |
| Maria | Vasiloglou | Switzerland | What healthcare professionals and end-users need in image-based nutrition apps? |
| Paul | Wadwa | USA | Challenges in implementing telehealth for diabetes care |
| Anders | Weber | Denmark | Raman Ni-BGM from conception to real world clinical device; are we there yet? |
| Stuart | Weinzimer | USA | Postprandial glucose control in advanced hybrid closed-Loop systems |
| Emma | Wilmot | UK | · Helping adults choose a safe and effective CGM in light of new national guidance |
| · AID experience in the real world in the United Kingdom | |||
| Leah | Wilson | USA | Artificial intelligence and decision support systems |
| Jamie | Wood | USA | Diabetes technology access in low and middle low-income countries: now or later? |
| Yariv | Yogev | Israel | Should we suggest weight loss during pregnancy for obese women with diabetes? |
| Dessi | Zaharieva | USA | · Is technology useful for breaking down barriers to exercise in diabetes? |
| · Sex differences in the management of exercise in the pediatric and adult population |